MAPT (multi-domain Alzheimer’s prevention trial): Results at 36 months

The MAPT trial was designed to assess the efficacy of supplementation with omega-3 fatty acid, multidomain intervention or a combination of the two interventions on the change of cognitive functions in subjects 70 years and older with subjective memory complaints for a period of 3 years. 1680 elderly subjects enrolled by 13 memory clinics, were randomized into one of the four intervention groups. Participants underwent cognitive (MMSE, CDR, COWAT, CNT, Digit symbol substitution test, Trail making test, Free and cued selective Reminding test), functional (SPPB, ADCS-ADL-PI) and biological assessments at M6, M12, M24 and M36 visits. The primary endpoint was a change of cognitive function at 3 years, as assessed by a composite cognitive test Z score. Interventions: 1/ Omega-3: 800 mg docosahexaenoic acid (DHA) per day, for 3 years. 2/ Multidomain intervention: training sessions in small groups (6–8 participants) in twelve 120-minute sessions over the first 2 months, then a 60-mn session per month in the following three areas: nutrition, physical activity, and cognition until the end of the 3 years. Individualized preventive outpatient visits exploring were also performed at baseline, M12 and M24. At baseline, the 4 groups were comparable for cognition, age, sex, and educational level. Primary endpoint (composite cognitive test including RL/RI- 16, MMSE orientations items, verbal fluency and WAIS test), secondary endpoints as well as safety data will be presented and discussed. This large and long-term clinical trial was designed to provide an evaluation of the efficacy and safety of multi-domain intervention and use of omega 3 in older adults with subjective memory complaints to prevent further cognitive decline.